| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.19▼ | 4.20▼ | 4.20▼ | 4.41▼ | 4.45▼ |
| MA10 | 4.19▼ | 4.21▼ | 4.24▼ | 4.44▼ | 4.51▼ |
| MA20 | 4.20▼ | 4.25▼ | 4.33▼ | 4.67▼ | 4.49▼ |
| MA50 | 4.21▼ | 4.39▼ | 4.46▼ | 4.53▼ | 4.53▼ |
| MA100 | 4.24▼ | 4.46▼ | 4.52▼ | 4.49▼ | 5.77▼ |
| MA200 | 4.33▼ | 4.54▼ | 4.84▼ | 4.50▼ | 7.14▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.002▲ | -0.015▼ | -0.057▼ | -0.002▼ |
| RSI | 30.718▼ | 28.539▼ | 27.452▼ | 37.009▼ | 46.118▼ |
| STOCH | 52.963 | 40.114 | 17.639▼ | 32.092 | 37.356 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -98.529▼ | -77.026▼ |
| CCI | -210.997▼ | -121.532▼ | -88.008 | -206.450▼ | -57.683 |
|
Tuesday, January 27, 2026 10:59 PM
(RTTNews) - Altimmune, Inc. (ALT), a late clinical-stage biopharmaceutical company, said it entered into an agreement with a new fundamental institutional investor for the purchase and sale of 17.05 ...
|
|
Tuesday, January 06, 2026 01:29 PM
(RTTNews) - Altimmune Inc. (ALT) announced that the U.S. FDA granted Breakthrough Therapy Designation for Pemvidutide, its balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of ...
|
|
Tuesday, January 06, 2026 08:53 AM
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide, a novel, investigational GLP-1/glucagon dual receptor agonist, for the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/03/26 | 4.202 | 4.2699 | 4.15 | 4.16 | 2,356,955 |
| 27/02/26 | 4.40 | 4.47 | 4.29 | 4.31 | 2,982,166 |
| 26/02/26 | 4.5501 | 4.56 | 4.38 | 4.46 | 1,889,700 |
| 25/02/26 | 4.59 | 4.61 | 4.49 | 4.56 | 2,034,417 |
| 24/02/26 | 4.52 | 4.83 | 4.52 | 4.57 | 2,938,992 |
| 23/02/26 | 4.34 | 4.64 | 4.34 | 4.52 | 3,177,697 |
| 20/02/26 | 4.49 | 4.51 | 4.36 | 4.38 | 4,121,527 |
| 19/02/26 | 4.46 | 4.53 | 4.27 | 4.49 | 3,212,139 |
| 18/02/26 | 4.50 | 4.55 | 4.415 | 4.46 | 2,792,441 |
| 17/02/26 | 4.56 | 4.64 | 4.48 | 4.50 | 1,883,442 |
|
|
||||
|
|
||||
|
|